NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA has agreed to cover Myriad Genetics' prostate cancer aggressiveness test Prolaris for patients who are at intermediate risk for the disease.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.